- Home
- TNGX vs ATAI Comparison
TNGX vs ATAI Comparison
Compare TNGX & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNGX | ATAI |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TNGX | ATAI |
|---|---|---|
| Price | $12.51 | $3.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $13.00 | ★ $13.86 |
| AVG Volume (30 Days) | 3.1M | ★ 4.0M |
| Earning Date | 02-26-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,501,000.00 | $3,018,000.00 |
| Revenue This Year | $52.80 | $956.49 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 53.29 | ★ 811.78 |
| 52 Week Low | $1.03 | $1.15 |
| 52 Week High | $13.46 | $6.75 |
Technical Indicators
Market Signals| Indicator | TNGX | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 62.52 | 40.17 |
| Support Level | $11.69 | $3.32 |
| Resistance Level | $12.96 | $3.98 |
| Average True Range (ATR) | 0.78 | 0.22 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 81.65 | 28.24 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.